Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts by Li, Qing et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
Polyol pathway and modulation of ischemia-reperfusion injury in 
Type 2 diabetic BBZ rat hearts
Qing Li1, Yuying C Hwang1, Radha Ananthakrishnan1, Peter J Oates2, 
Dennis Guberski3 and Ravichandran Ramasamy*1
Address: 1Division of Surgical Science, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, 
USA, 2Pfizer Global Research, Groton, CT, USA and 3Biomedical Research Models Inc, Worcester, MA, USA
Email: Qing Li - ql2109@columbia.edu; Yuying C Hwang - yh218@columbia.edu; Radha Ananthakrishnan - ra2197@columbia.edu; 
Peter J Oates - peter.j.oates@pfizer.com; Dennis Guberski - dguberski@biomere.com; Ravichandran Ramasamy* - rr260@columbia.edu
* Corresponding author    
Abstract
We investigated the role of polyol pathway enzymes aldose reductase (AR) and sorbitol
dehydrogenase (SDH) in mediating injury due to ischemia-reperfusion (IR) in Type 2 diabetic BBZ
rat hearts. Specifically, we investigated, (a) changes in glucose flux via cardiac AR and SDH as a
function of diabetes duration, (b) ischemic injury and function after IR, (c) the effect of inhibition of
AR or SDH on ischemic injury and function. Hearts isolated from BBZ rats, after 12 weeks or 48
weeks diabetes duration, and their non-diabetic littermates, were subjected to IR protocol.
Myocardial function, substrate flux via AR and SDH, and tissue lactate:pyruvate (L/P) ratio (a
measure of cytosolic NADH/NAD+), and lactate dehydrogenase (LDH) release (a marker of IR
injury) were measured. Zopolrestat, and CP-470,711 were used to inhibit AR and SDH,
respectively. Myocardial sorbitol and fructose content, and associated changes in L/P ratios were
significantly higher in BBZ rats compared to non-diabetics, and increased with disease duration.
Induction of IR resulted in increased ischemic injury, reduced ATP levels, increases in L/P ratio, and
poor cardiac function in BBZ rat hearts, while inhibition of AR or SDH attenuated these changes
and protected hearts from IR injury. These data indicate that AR and SDH are key modulators of
myocardial IR injury in BBZ rat hearts and that inhibition of polyol pathway could in principle be
used as a therapeutic adjunct for protection of ischemic myocardium in Type 2 diabetic patients.
Introduction
Cardiovascular disease represents the major cause of mor-
bidity and mortality in patients with diabetes. Diabetic
patients with coronary artery disease have high morbidity
and mortality due to cardiovascular complications, with
the incidence of heart failure after myocardial infarction
significantly greater in patients with diabetes than in non-
diabetic patients [1-4]. Ventricular myocardial biopsies
from diabetic patients exhibit significant increases in
necrotic cardiomyocytes relative to biopsies from non-
diabetic patients [5,6], indicating impairment in myocar-
dial ischemic tolerance. In addition, diabetic patients also
exhibit cardiomyopathy independent of coronary artery
disease characterized by restrictive physiology [5-7].
Though clinical literature is incontrovertible in demon-
strating increased cardiac injury in diabetes after myocar-
dial infarction, experimental studies using animal models
have yielded mixed results in this regard.
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Studies investigating cardiovascular changes in Type 2 dia-
betic rats have employed spontaneously diabetic Otsuka
Long-Evans Tokushima fatty (OLETF), Goto-Kakizaki
(GK), and Zucker Diabetic Fatty (ZDF) rats [8-12]. A spon-
taneous Type 2 diabetic rat BBZDR/Wor (BBZ), from Bio-
medical Research Models (Worcester, MA) has been
shown to closely mimic human disease. This model is
characterized by spontaneous onset of diabetes at approx-
imately 70 days of age, preceded by obesity. It shows insu-
lin resistance with hyperglycemia and hyperinsulinemia
as well as hyperlipidemia, hypercholestrolemia and mild
hypertension [13-15].
The polyol pathway enzyme aldose reductase catalyzes the
reduction of aldo sugars and other saturated and unsatu-
rated aldehydes [16-20]. This enzyme constitutes the first
and the rate limiting step of the polyol pathway. This
pathway has been suggested to play an important role in
the development of vascular and neurological complica-
tions in diabetes [21-26]. Inhibition of aldose reductase
has been shown to ameliorate vascular and other compli-
cations in diabetics [21-26].
Our early studies using the Type 1 diabetic BB rat hearts
demonstrated that aldose reductase is a key component of
ischemia-reperfusion injury and that inhibition of this
pathway reduced injury and improved functional and
metabolic recovery on reperfusion [27,28]. In this study,
we investigated the role of polyol pathway in mediating
injury due to ischemia-reperfusion in Type 2 diabetic BBZ
rat hearts. The results from Type 2 diabetic BBZ rat hearts
in this study demonstrate (a) increased activities of polyol
pathway enzymes aldose reductase and sorbitol dehydro-
genase with duration of diabetes, (b) increased ischemic
injury and poor functional recovery after ischemia-reper-
fusion, (c) reduced ischemic injury and improved func-
tional recovery consequent to inhibition of aldose
reductase or sorbitol dehydrogenase.
Methods
All studies were performed with the approval of the Insti-
tutional Animal Care and Use Committee at Columbia
University, New York. This investigation conforms with
the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH pub-
lication No. 85-23, 1996). In our studies we chose the
Type 2 BBZDR/Wor diabetic rats. The Type 2 BBZDR/Wor
rats are characterized by spontaneous onset of diabetes at
about 70 days of age, which is preceded by obesity. These
rats also exhibit insulin resistance with hyperglycemia and
hyperinsulinemia, as well as hyperlipidemia, hypercho-
lesterolemia, and mild hypertension [13-15]. The lean
non-diabetic littermates were use as controls in this study.
All rats were received from Biomedical Research Models,
Worcester, MA.
Isolated Perfused Heart Model
Rats (300–400 g) were anesthetized by injecting keta-
mine/xylazine (80 mg/kg and 10 mg/kg; I.P.) and the
hearts rapidly excised and placed in ice cold saline. Hearts
were retrograde perfused (in a non-recirculating mode)
through the aorta using an isovolumic perfusion system as
published earlier [29,30]. Left ventricular developed pres-
sure (LVDP), and left ventricular end diastolic pressure
(EDP) were measured using a fluid filled latex balloon in
the left ventricle with high pressure tubing connected to a
pressure transducer [29,30]. Cardiac function measure-
ments were recorded on a 4-channel ADI recorder. The
perfusate consisted of NaCl 118 mM, KCl 4.7 mM, CaCl2
1.2 mM, MgCl2 1.2 mM, NaHCO3 25 mM, glucose 5 mM,
palmitate 0.4 mM, bovine serum albumin 0.4 mM, and
insulin 70 milliunits/L. The perfusion apparatus was
tightly temperature controlled, with heated baths being
used for the perfusate and for the water jacketing around
the perfusion tubing to maintain heart temperature at 37
± 0.2°C under all conditions. The oxygenation chamber
in our perfusion system maintains perfusate Po2 > 600
mmHg. All rat hearts were paced at 300 beats/min with
the use of pacing electrodes placed on the right atrium.
Hearts were subjected to 30 min of normoxic perfusion at
a flow rate of 12.5 ml/min followed by 50 min of severe
low-flow ischemia (perfusate flow reduced to 0.7 ml/min)
and 60 min of reperfusion at a normal flow rate (12.5 ml/
min).
To determine the mechanisms by which flux via aldose
reductase impacts ischemic injury, experiments were per-
formed in the presence of inhibitors of AR (ARI) or sorbi-
tol dehydrogenase (SDI). The studies involving the use of
SDI were to establish if the flux via SDH and accompany-
ing increases in cytosolic NADH/NAD+  are important
event that mediates ischemic injury. After the equilibra-
tion period of 30 min, hearts (n = 6) from Type 2 BBZ and
non-diabetic littermate rats were perfused with modified
Krebs-Henseleit buffer containing 1 μM ARI zopolrestat
(unbound [31]) or 200 nM SDI CP-470,711 starting 10
min prior to ischemia and continued throughout
ischemia and reperfusion. The dose of ARI and SDI used
here were based on our earlier studies [32-35].
Biochemical Assays
Tissue levels of lactate, pyruvate, sorbitol, and fructose
were measured as published by us earlier [32-35]. Inte-
grated release of lactate dehydrogenase during reper-
fusion, a marker of ischemic injury [36], was measured as
previously published in the literature.
Western blot studies
Extracts from rat hearts were prepared by tissue homoge-
nization in cell lysis buffer as previously described [32-34]Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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and were subjected to further analysis. The protein con-
centration was determined using a DC Protein Assay kit
(Bio-Rad). Equal amounts of protein were separated by
SDS-PAGE (4–12% gradient gels), and proteins were
transferred to a polyvinylidene difluoride membrane
(Invitrogen), that was probed with primary antibodies.
The antibodies were diluted at 1:1,000. The primary anti-
bodies used were anti-aldose reductase IgG (custom pre-
pared by Cambridge Research Biochemicals, UK), anti-
sorbitol dehydrogenase IgG (custom prepared by Cam-
bridge Research Biochemicals, UK), and anti-β-actin IgG
(Sigma). Blots were visualized with a Phototop-Horserad-
ish Peroxidase Western Blot Detection System (Cell Sign-
aling), and quantitative analysis was performed using
Image Quant TL software (Amersham).
Statistical Methods
Data were analyzed using INSTAT (GraphPad, San Diego,
CA) software operating on an IBM compatible personal
computer. Differences between different groups were
assessed using ANOVA with subsequent Student-New-
man-Keuls multiple comparisons post-tests if the p value
for ANOVA was significant. A p value of less than 0.05 was
used to reject the null hypothesis. All data are expressed as
mean ± SD.
Results
Animal Characteristics
Body weight, heart weight, and serum metabolite data for
age-matched non-diabetic (ND) and Type 2 diabetic
(DM) rats are summarized in Table 1. As expected, at 12
and 48 weeks of diabetes, DM rats were significantly heav-
ier than their age-matched ND counterparts (p < 0.05).
Serum glucose was elevated in the DM group; since the
animals were in the fed state, this presumably reflects the
glucose intolerance present at this age. In both the dia-
betic groups (12 weeks & 48 weeks duration), glucose lev-
els were elevated by about 4 fold in DM vs ND rats (p <
0.05). Fatty acids were also elevated in both the 12 weeks
and 48 weeks diabetic rats compared to their age-matched
non-diabetics (p < 0.05). Insulin levels in 12-week DM
rats were higher than in age matched ND rats. In the 48-
week DM rats, insulin declined markedly and was signifi-
cantly lower than in the age-matched ND rats. These data
are entirely consistent with previously published data on
Type 2 diabetic rats [37,38] and clearly demonstrate that
the BBZ rats exhibit a Type 2 diabetic phenotype.
Polyol pathway in Type 2 diabetic rat hearts under 
baseline normoxic conditions
To test the hypothesis that diabetes may increase flux via
aldose reductase and sorbitol dehydrogenase, sorbitol
and fructose content were measured in hearts under nor-
moxic conditions from Type 2 diabetic rats (Fig 1A). Sorb-
itol and fructose content increased in Type 2 diabetic rat
hearts compared to non-diabetic rat hearts (Fig 1A &1B).
The changes in sorbitol and fructose were also observed as
a function of diabetes duration. Inhibition of AR attenu-
ated both sorbitol and fructose content in diabetic rats,
whereas inhibition of SDH attenuated fructose content in
diabetic hearts (Figure 1a &1b). These data are consistent
with increases in flux via polyol pathway as a function of
diabetes duration.
Western blot analysis of AR and SDH protein expression
in non-diabetic and 12 week diabetic hearts (Fig 2A–B)
did not reveal any differences under baseline normoxic
conditions, where as significant increases in AR and SDH
expression levels were observed in 48 weeks diabetic
hearts (Figure 2C &2D).
Polyol pathway and ischemia-reperfusion injury in Type 2 
diabetic rat hearts
LDH release on reperfusion, a marker of myocardial
ischemia-reperfusion injury, was significantly greater in
12 week diabetic BBZ when compared on age matched
non-diabetic controls (Figure 3A). Similarly, LDH release
on reperfusion was also significantly greater in 48 weeks
diabetic compared to its age matched non-diabetic rat
hearts (Figure 3B). Comparison of LDH release indicated
that injury after ischemia-reperfusion was significantly
greater in 48 weeks diabetic than in 12-week diabetic rat
hearts (Figure 4C). Treatment of diabetic hearts (12 weeks
& 48 weeks) with an ARI or SDI attenuated LDH release,
indicating protection of from ischemia-reperfusion injury
(Figure 3A &3B). We have shown earlier that treatment
with ARI or SDI protects non-diabetic rat hearts from
ischemia-reperfusion injury [32-34].
Table 1: Body weight and serum metabolite data from aged matched non-diabetic (ND) and Type 2 diabetic rats (DM)
12 wk 48 wk
ND (n = 9) DM (n = 6) ND (n = 7) DM (n = 6)
Body weight, g 292 ± 12 412 ± 29* 386 ± 32 472 ± 19*
Glucose, mM 8.1 ± 0.4 32.9 ± 4.2* 11.9 ± 1.1 46.6 ± 3.8*
FFA, mM 0.36 ± 0.3 0.51 ± 0.5* 0.65 ± 0.5 1.12 ± 0.09*
Insulin, nM 0.69 ± 0.09 2.59 ± 0.22* 0.51 ± 0.06 0.23 ± 0.05*,#
* P < 0.05 vs age matched ND rats, #p < 0.05 vs 12 Wk DM rats.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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Products of polyol pathway, sorbitol (A) and fructose (B) were measured in the hearts from 12 weeks and 48 weeks diabetic  (DM) BBZ rats and their age matched non-diabetic (ND) controls Figure 1
Products of polyol pathway, sorbitol (A) and fructose (B) were measured in the hearts from 12 weeks and 48 
weeks diabetic (DM) BBZ rats and their age matched non-diabetic (ND) controls. Diabetes duration of 12 weeks 
(n = 9) and 48 weeks (n = 6) were used in this study. ARI denotes treatment with the aldose reductase inhibitor zopolrestat, 
while SDI denotes treatment with sorbitol dehydrogenase inhibitor.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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Probing of the expression of aldose reductase (AR) (A) and sorbitol dehydrognease (SDH) (B) in hearts from 12 weeks dia- betic BBZ and age matched non-diabetic littermate rat hearts using western blots Figure 2
Probing of the expression of aldose reductase (AR) (A) and sorbitol dehydrognease (SDH) (B) in hearts from 
12 weeks diabetic BBZ and age matched non-diabetic littermate rat hearts using western blots. Expression of 
AR (C) and SDH (D) were also probed in hearts from 48 weeks diabetic BBZ and age matched non-diabetic littermates. Equal 
amounts of protein were subjected to Western blotting using anti-AR IgG (A) or anti-SDH IgG; blots were then stripped and 
reprobed using anti-β actin IgG. Representative blots for each of the groups is presented here. Six hearts per group were used 
in this study.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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Polyol pathway and myocardial function during ischemia-
reperfusion
Figure 4 illustrates the changes in left ventricular devel-
oped pressure (LVDP), left ventricular end-diastolic pres-
sure (EDP), and myocardial oxygen consumption in all
four groups of hearts. LVEDP was set to 5–8 mmHg at the
beginning of the perfusion period and increased in both
the groups to a maximum after ~15 min of ischemia.
LVDP under baseline conditions were significantly
reduced in untreated 12-week diabetic compared to non-
diabetic rat hearts (Figure 4A). After subjecting hearts to
ischemia-reperfusion, LVDP recovery was significantly
impaired in 12 week diabetic compared to non-diabetic
control hearts (Figure 5B). Treatment of 12 weeks diabetic
rat hearts with an ARI or SDI improved LVDP function
under baseline (Figure 5A) and reperfusion conditions
(Fig 4B). EDP at the end of ischemic period was signifi-
cantly increased in untreated 12 week diabetic hearts (Fig-
ure 4C) compared to all other groups.
LVDP changes in untreated 48 weeks diabetic rat hearts
were also impaired under baseline and reperfusion (Fig-
ure 4D, E respectively) in comparison with non-diabetic
rat hearts. Treatment of the diabetic rat hearts with an ARI
or SDI improved LVDP function under baseline and reper-
fusion conditions. End-ischemic EDP was significantly
increased in 48 weeks diabetic rat hearts (Figure 4F) in
comparison with non-diabetics. ARI and SDI treatment
attenuated the increases in end-ischemic EDP in diabetic
rat hearts. End ischemic EDP rose to 30 mm Hg in 12
week diabetic hearts, whereas it rose to 50 mmHg in 48
weeks diabetic hearts. The EDP data indicate that ischemic
Lactate dehydrogenase release (U/g dry wt) during 60 minutes of reperfusion, a marker of ischemic injury in age-matched non- diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol dehy- drogenase inhibitor (BBZ-SDI) rat hearts Figure 3
Lactate dehydrogenase release (U/g dry wt) during 60 minutes of reperfusion, a marker of ischemic injury in 
age-matched non-diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-
ARI), BBZ treated with sorbitol dehydrogenase inhibitor (BBZ-SDI) rat hearts. Diabetes duration of 12 weeks (n = 
9) (A) and 48 weeks (n = 6) (B) were used in this study. Comparison of LDH release in 12 weeks diabetic and 48 weeks dia-
betic BBZ rat hearts (C).Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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contracture was significantly greater with diabetes dura-
tion.
Flux via Polyol pathway and lactate/pyruvate ratio
The lactate/pyruvate (L/P) ratio reflects the cytosolic ratio
of NADH/NAD+. L/P ratios were measured in freeze-
clamped heart tissue extracts. As shown in Table 2, the
baseline L/P ratios were significantly higher in Type 2 dia-
betic hearts. Duration of diabetes further increased the L/
P ratios. Pharmacological inhibition of aldose reductase
or sorbitol dehydrogenase lowered the L/P ratio in Type 2
diabetic rat.
To determine if the rise in cytosolic NADH/NAD+ ratio is
a critical component of aldose reductase mediated
ischemic injury, hearts from Type 2 were subjected to
ischemia-reperfusion in the presence of AR or SDH inhib-
itor. Flux via aldose reductase and sorbitol dehydrogenase
results in conversion of NAD+ to NADH thus influencing
cytosolic NADH/NAD+ ratio; hence inhibition of either
aldose reductase or sorbitol dehydrogenase would limit
such changes. Figure 5A demonstrates that end ischemic
cytosolic L/P ratio was reduced in Type 2 diabetic rat
hearts by inhibiting aldose reductase or sorbitol dehydro-
genase. These data demonstrate that NADH/NAD+
changes are linked to polyol pathway mediated ischemic
injury in hearts.
Polyol pathway and ATP changes during ischemia and 
reperfusion
To determine changes in myocardial energy metabolism,
ATP content during ischemia and reperfusion was meas-
ured in all groups of hearts. ATP content was significantly
reduced in untreated diabetic hearts compared to non-
diabetics at the end of ischemia and reperfusion (Figure
5B &5C). Treatment with an ARI or SDI improved ATP
Left ventricular developed pressure (LVDP) recovery, expressed as mmHg, in age matched non-diabetic (ND), Type 2 diabetic  (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol dehydrogenase inhibitor (BBZ-SDI)  rat hearts under baseline (A, D) and reperfusion (B, E) conditions Figure 4
Left ventricular developed pressure (LVDP) recovery, expressed as mmHg, in age matched non-diabetic (ND), 
Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol 
dehydrogenase inhibitor (BBZ-SDI) rat hearts under baseline (A, D) and reperfusion (B, E) conditions. Left ven-
tricular end diastolic pressure (EDP), expressed as mmHg, in ND, BBZ, BBZ-ARI, BBZ-SDI at the end of ischemic period (C, 
F). Diabetes duration of 12 weeks (A, B, C) (n = 9) and 48 weeks (D, E, F) (n = 6) were used in this study. * P < 0.05 vs ND, 
BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing LVDP at baseline, @ P < 0.05 vs ND, 
BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing LVDP at reperfusion, #P < 0.05 vs ND, 
BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing End-ischemic EDP.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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content in diabetic rat hearts under all perfusion condi-
tions (Figure 5B &5C).
Discussion
Aldose reductase pathway has been implicated in the
pathogenesis of diabetic vascular complications. In this
study, we investigated if polyol pathway is an important
player in mediating ischemia and reperfusion injury in
type 2 diabetic BBZ rat hearts. The data presented here
demonstrates that flux via aldose reductase and sorbitol
dehydrogenase is increased in type 2 diabetic rat hearts
and that these increases play key roles in determining the
extent of ischemic damage.
Studies in BBZ rats showed significant increases in nerve
sorbitol and fructose contents when compared to those in
non-diabetic littermates [14]. It was also shown that
increases in nerve sorbitol continued with duration of dia-
betes, whereas nerve fructose content did not follow that
trend in the BBZ rat [14]. We show here that flux via
aldose reductase and sorbitol dehydrogenase continues to
increase with duration of diabetes in the BBZ rat hearts.
Furthermore, the increases in protein expression of aldose
reductase and sorbitol dehydrogenase coupled with
increased hyperglycemia presented here may, in part, be
responsible for the increased flux via these enzymes in 48
weeks diabetic BBZ rat hearts. However, it is well estab-
lished that glucose flux through aldose reductase is
increased in diabetes. Since aldose reductase has a high
Km for glucose, it would mean that increasing hyperglyc-
emia is likely to increase flux via polyol pathway propor-
tionately. At 48 weeks of diabetes, the degree of
hyperglycemia is significantly greater than at 12 weeks,
with far lower insulin levels. The greater glucose availabil-
(A) Lactate/pyruvate ratios in age matched non-diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhib- itor (BBZ-ARI), BBZ treated with sorbitol dehydrogenase inhibitor (BBZ-SDI) rat hearts at the end of ischemic period Figure 5
(A) Lactate/pyruvate ratios in age matched non-diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with 
aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol dehydrogenase inhibitor (BBZ-SDI) rat 
hearts at the end of ischemic period. Six hearts were studied per group. ATP, expressed as μmoles/g dry wt, age matched 
non-diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol 
dehydrogenase inhibitor (BBZ-SDI) rat hearts at the end of ischemia (B), and at the end of reperfusion (C). Six hearts were 
studied per group. *P < 0.05 vs ND, BBZ-ARI, and BBZ-SDI comparing ATP at the end of Ischemia, #P < 0.05 vs ND, BBZ-ARI, 
and BBZ-SDI comparing ATP at the end of reperfusion.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
Page 9 of 11
(page number not for citation purposes)
ity over time (amount and duration) is, in part, a key rea-
son for the increased flux through aldose reductase.
Flux via polyol pathway has been associated with changes
in cytosolic NADH/NAD+ the ratio [32-35,39-41]. These
changes in cytosolic redox ratio have been demonstrated
in ischemic and diabetic state [32-35,39-41]. In this study,
we demonstrate that cytosolic lactate/pyruvate ratio, a
measure of cytosolic NADH/NAD, is associated with
increases in polyol pathway activity in type 2 diabetic BBZ
rat hearts. These data are consistent with our earlier stud-
ies [32-35], demonstrating increased flux via polyol path-
way during ischemia resulting in increased cytosolic
NADH/NAD+. The data presented here show that inhibi-
tion of aldose reductase or sorbitol dehydrogenase atten-
uates increases in cytosolic NADH/NAD ratio in type 2
diabetic rat hearts and is associated with changes in ATP
levels and protection of hearts from IR injury.
Although the present results show that elevated NADH/
NAD+ can be blocked by either ARI or SDI treatment in
this preclinical model, extreme caution should be exer-
cised in regard to extrapolation of SDH inhibition to the
clinical arena. This is warranted based on a) reports of
increased neuronal axonal dystrophy observed in rat gan-
glia, [42]. and b) the discontinuation of an SDI clinical
trial for adverse events that possibly might have been
mechanism-related (Landau Z et al., manuscript in sub-
mission). In the diabetic rat model, increased occurrence
of ganglionic lesions with SDI treatment notably was pre-
vented by concurrent administration of an ARI [43].
Aldose reductase pathway inhibition attenuated the rise in
EDP during ischemia in diabetic hearts. Several studies
have shown that the attenuation of the rise in EDP by
interventions is linked to the maintenance of intracellular
sodium and calcium homeostasis [44-49]. In our earlier
studies, we have shown that inhibition of aldose reduct-
ase attenuated the rise in intracellular sodium and cal-
cium during ischemia and reperfusion in Type 1 BB/WOR
diabetic hearts [48]. Protection of the Type 2 diabetic
ischemic hearts by aldose reductase or sorbitol dehydro-
genase inhibitors in this study is presumably due to atten-
uation of changes in sodium and calcium homeostasis
during ischemia – reperfusion. However, further studies
are required to confirm this speculation.
Overwhelming clinical evidence indicate that the diabetic
heart in humans is sensitive to ischemic injury [1-6].
However, the animal studies addressing this issue have
resulted in ambiguous results. In the type 2 ZDF rat hearts,
in-vivo ischemia – reperfusion resulted in increased inf-
arct size and poor functional outcome [50]. A study by
Wang & Chatham, using isolated perfused heart models,
showed that despite greater contracture during low flow
ischemia the diabetic ZDF rat hearts exhibited improved
functional recovery on reperfusion [9]. Our studies pre-
sented here in isolated perfused hearts demonstrate that
ischemia/reperfusion increases injury and impairs func-
tional recovery in type 2 diabetic BBZ rat hearts. In our
studies and in the one by Wang and Chatham [9],
ischemic contracture during low flow ischemia was signif-
icantly greater in Type 2 diabetic rat hearts than in nondi-
abetics. In our studies, increased ischemic contracture was
also associated with greater ischemic injury and poor
functional recovery on reperfusion. Thus, the data pre-
sented in our study are consistent with earlier studies
demonstrating association between ischemic contracture,
ischemic injury and functional recovery.
Earlier studies by us [27,28,32,33,35] and others [51,52]
demonstrated that inhibition of aldose reductase affords
protection to myocardium against ischemia-reperfusion
injury. It should be noted that injury to myocardium
occurs both at the ischemic and reperfusion period. The
presence of aldose reductase inhibitor throughout
ischemic and reperfusion period indicates that injury dur-
ing both ischemic and reperfusion phase was attenuated
by aldose reductase inhibition.
One aspect of injury to the myocardium not addressed by
our data is the role of highly reactive oxygen species in
mediating injury in the Type 2 diabetic hearts. Excess gen-
eration of highly reactive free radicals, both due to hyper-
glycemia and ischemia-reperfusion injury [53] can
exacerbate injury in diabetics. The impact of aldose
reductase inhibition in attenuating highly reactive free
radicals, during ischemia-reperfusion, needs to be exam-
ined in the Type 2 diabetic hearts.
Table 2: Lactate:pyruvate ratios in Type 2 diabetic hearts
Group n Lactate/Pyruvate ratio
Non-diabetic controls 12 16.8 ± 3.2
Type 2 diabetics
12 weeks duration 9 41.4 ± 8.8*
48 weeks duration 5 77.5 ± 12.2*
Aldose reductase inhibited Type 2 diabetics
12 weeks duration 7 7.2 ± 1.8
48 weeks duration 5 10.5 ± 3.2
Sorbitol dehydrogenase inhibited Type 2 diabetics
12 weeks duration 7 8.9 ± 2.1
48 weeks duration 5 12.6 ± 3.4
* p < 0.05 vs non-diabetic controls. The lactate/pyruvate ratios were 
measured after perfusion for one hour under normoxic conditions.Cardiovascular Diabetology 2008, 7:33 http://www.cardiab.com/content/7/1/33
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Conclusion
In summary, we demonstrate that fluxes via polyol path-
way enzymes aldose reductase and sorbitol dehydroge-
nase are increased in type 2 diabetic BBZ rat hearts as a
function of disease duration. The increases in flux via
these enzymes were accompanied by increased lactate/
pyruvate ratio. Inhibition of aldose reductase or sorbitol
dehydrogenase reduced ischemic injury, improved func-
tional recovery and ATP levels after ischemia – reperfusion
in diabetic rat hearts. These data suggest that inhibition of
polyol pathway could in principle be used as a therapeutic
adjunct for protecting ischemic myocardium in type 2 dia-
betic patients.
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